The U.S. Food and Drug Administration pronounced on Friday that it had approved a new drug, called Kadcyla, for patients with HER2-positive, late-stage breast cancer.
According to a National Cancer Institute, HER2 is a protein concerned in normal dungeon growth. It is found on some forms of cancer cells, including breast and ovarian. The FDA records that in HER2-positive breast cancers, a increasing volume of a HER2 protein aids in cancer dungeon expansion and survival.
Kadcyla is designed for patients who were formerly treated with trastuzumab, another anti-HER2 therapy, and taxanes, a category of chemotherapy drugs typically used for a diagnosis of breast cancer.
"Kadcyla is trastuzumab connected to a drug called DM1 that interferes with cancer dungeon growth," pronounced Richard Pazdur, executive of a Office of Hematology and Oncology Products in
Read full article: http://www.independent.co.uk/news/world/europe/vatican-spokesman-father-federico-lombardi-criticises-rumours-surrounding-popes-resignation-8507223.html
Source:
http://www.news.ezonearticle.com/2013/02/23/fda-approves-new-drug-for-late-stage-breast-cancer/
0 comments:
Post a Comment